← Ablatotech Vitals
GeneralMedicine EvidenceDigest

Current Evidence on the Use of Low-Carbohydrate Diets for Non-Alcoholic Fatty Liver Disease Management in Primary Care

GeneralMedicine · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
October 19, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Low-carbohydrate diets (LCDs) have shown potential to reduce intrahepatic fat and improve metabolic parameters in patients with non-alcoholic fatty liver disease (NAFLD). Meta-analyses of randomized trials indicate that LCDs can decrease liver fat content independent of weight loss. However, observational data suggest that habitual adherence to LCDs may paradoxically increase NAFLD risk in some populations. Current evidence supports LCDs as a viable dietary strategy for NAFLD management in primary care, but individualized approaches and further long-term studies are needed to clarify benefits and risks (Bueno et al., 2020; Worm et al., 2020; Yiannakou et al., 2022).

Clinical bottom line

Low-carbohydrate diets (LCDs) have shown potential to reduce intrahepatic fat and improve metabolic parameters in patients with non-alcoholic fatty liver disease (NAFLD). Meta-analyses of randomized trials indicate that LCDs can decrease liver fat content independent of weight loss. However, observational data suggest that habitual adherence to LCDs may paradoxically increase NAFLD risk in some populations. Current evidence supports LCDs as a viable dietary strategy for NAFLD management in primary care, but individualized approaches and further long-term studies are needed to clarify benefits and risks (Bueno et al., 2020; Worm et al., 2020; Yiannakou et al., 2022).

What the evidence shows

Bueno et al. (2020) performed a meta-analysis of randomized controlled trials examining LCDs in individuals with NAFLD. They found significant reductions in intrahepatic lipid content and improvements in liver enzymes compared to control diets, suggesting a direct effect of carbohydrate restriction on liver fat independent of weight loss.

Worm et al. (2020) reviewed dietary strategies targeting intrahepatic fat, highlighting that LCDs reduce de novo lipogenesis and improve insulin sensitivity, key mechanisms in NAFLD pathogenesis. They emphasize that LCDs may confer metabolic benefits beyond simple caloric restriction.

Conversely, Yiannakou et al. (2022) analyzed data from the Framingham Heart Study and reported that higher adherence to LCDs was associated with increased NAFLD risk, possibly reflecting differences in diet quality, fat sources, or population characteristics.

Chitturi et al. (2013) provide a primary care perspective on NAFLD management, recommending lifestyle modification including dietary changes as first-line therapy but cautioning that no single diet is universally superior.

Gill et al. (2006) reviewed popular diets and concluded that while weight loss remains central, LCDs may offer particular advantages in reducing liver fat and improving metabolic syndrome components.

Gunaseelan et al. (2021) present a case report and literature review supporting carbohydrate restriction as a practical approach to NAFLD management, noting patient adherence and individualized counseling as critical factors.

Caveats and uncertainty

Heterogeneity in LCD definitions, duration, and macronutrient composition complicates interpretation.

Most randomized trials are short-term with small sample sizes; long-term safety and sustainability data are limited.

Observational studies may be confounded by unmeasured dietary and lifestyle factors influencing NAFLD risk.

The impact of LCDs on fibrosis progression and clinical outcomes remains unclear.

Patient adherence and dietary quality (e.g., types of fats consumed) influence effectiveness and safety.

How this may change practice

Primary care clinicians can consider LCDs as a dietary option for NAFLD patients, especially those with insulin resistance or metabolic syndrome.

Dietary counseling should emphasize quality of carbohydrate and fat sources alongside carbohydrate quantity.

Regular monitoring of liver function and metabolic parameters is advisable during dietary interventions.

Shared decision-making incorporating patient preferences and comorbidities will optimize adherence and outcomes.

Further research is needed to establish standardized LCD protocols and long-term effects on liver-related morbidity and mortality.


References

  1. Bueno NB, et al. Low-carbohydrate diets and intrahepatic lipid content in individuals with non-alcoholic fatty liver disease: Evidence from a meta-analysis of randomized trials. Clin Nutr. 2020; DOI:10.1016/j.clnu.2019.11.026
  2. Worm N, et al. Beyond Body Weight-Loss: Dietary Strategies Targeting Intrahepatic Fat in NAFLD. Nutrients. 2020; DOI:10.3390/nu12051316
  3. Yiannakou I, et al. Low-Carbohydrate Diets, but Not Low-Fat Diets, Increase Non-alcoholic Fatty Liver Disease Risk in the Framingham Heart Study. Curr Dev Nutr. 2022; DOI:10.1093/cdn/nzac067.082
  4. Chitturi S, et al. A Primary Care Perspective of Fatty Liver: Diagnosis, Management, Prescribing, and when to Refer. Non-Alcoholic Fatty Liver Disease. 2013; DOI:10.1002/9781118556153.ch8
  5. Gill HK, et al. Non-alcoholic fatty liver disease and the metabolic syndrome: Effects of weight loss and a review of popular diets. Are low carbohydrate diets the answer? World J Gastroenterol. 2006; DOI:10.3748/wjg.v12.i3.345
  6. Gunaseelan L, et al. Non-alcoholic Fatty Liver Disease and Carbohydrate Restricted Diets: A Case Report and Literature Review. Cureus. 2021; DOI:10.7759/cureus.18641

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team